

Joseph Gligorov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7133564/publications.pdf>

Version: 2024-02-01

191
papers

7,597
citations

66234

42
h-index

60497

81
g-index

266
all docs

266
docs citations

266
times ranked

8698
citing authors

#	ARTICLE	IF	CITATIONS
1	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
2	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495.	0.6	454
3	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	0.6	402
4	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	0.6	393
5	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management. <i>Cancer</i> , 2007, 110, 1376-1384.	2.0	382
6	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	0.9	291
7	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	0.9	269
8	First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3lg) enhances immune responses and antitumor activity. <i>Journal of Translational Medicine</i> , 2010, 8, 71.	1.8	209
9	Preclinical Pharmacology of the Taxanes: Implications of the Differences. <i>Oncologist</i> , 2004, 9, 3-8.	1.9	194
10	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 962-970.	5.1	173
11	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 375-384.	5.1	160
12	Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2678-2684.	0.8	122
13	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987.	0.6	122
14	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1351-1360.	5.1	120
15	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1269-1278.	5.1	118
16	Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. <i>Annals of Oncology</i> , 2008, 19, 1110-1116.	0.6	107
17	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. <i>Lancet</i> , The, 2019, 393, 2591-2598.	6.3	102
18	Adjuvant treatments for triple-negative breast cancers. <i>Annals of Oncology</i> , 2012, 23, vi40-vi45.	0.6	94

#	ARTICLE	IF	CITATIONS
19	Efficacy of Circulating Tumor Cell Countâ€“Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptorâ€“Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	3.4	92
20	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. <i>Annals of Oncology</i> , 2014, 25, 1570-1577.	0.6	90
21	Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients. <i>Clinical Chemistry</i> , 2005, 51, 1093-1101.	1.5	82
22	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
23	Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 198-207.	2.0	79
24	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 437-446.	1.1	70
25	Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. <i>Annals of Oncology</i> , 2021, 32, 1051-1053.	0.6	68
26	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) Å± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2020, 31, S1147-S1148.	0.6	66
27	The extracellular domain of Her2 in serum as a biomarker of breast cancer. <i>Laboratory Investigation</i> , 2018, 98, 696-707.	1.7	62
28	Pregnancy-associated breast cancers: Do they differ from other breast cancers in young women?. <i>Breast</i> , 2012, 21, 550-555.	0.9	59
29	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptorâ€“positive, human epidermal growth factor receptor 2â€“negative early-stage breast cancer. <i>European Journal of Cancer</i> , 2016, 66, 104-113.	1.3	59
30	The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 95-113.	1.1	55
31	Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 91-102.	2.0	53
32	Multiple synchronous (multifocal and multicentric) breast cancer: Clinical implications. <i>Surgical Oncology</i> , 2010, 19, e115-e123.	0.8	52
33	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017, 28, 103-109.	0.6	52
34	Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years. <i>Cancer</i> , 2009, 115, 5155-5165.	2.0	51
35	Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6587.	1.8	51
36	Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. <i>Annals of Oncology</i> , 2005, 16, 411-418.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 469-475.	1.9	48
38	Pertuzumab and trastuzumab: the rationale way to synergy. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016, 88, 565-577.	0.3	47
39	Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. <i>European Journal of Cancer</i> , 2017, 82, 230-236.	1.3	46
40	The role of taxanes in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1073-1094.	0.9	45
41	Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 124-133.	2.0	45
42	Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 53-66.	1.1	44
43	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. <i>European Journal of Human Genetics</i> , 2018, 26, 1732-1742.	1.4	44
44	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015, 20, 873-879.	1.9	43
45	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 745-753.	1.1	41
46	Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. <i>Lung</i> , 2009, 187, 69-74.	1.4	40
47	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. <i>European Journal of Cancer</i> , 2017, 86, 82-90.	1.3	39
48	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	1.3	38
49	High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers. <i>Annals of Oncology</i> , 2021, 32, 1294-1295.	0.6	38
50	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016, 7, 18531-18540.	0.8	38
51	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. <i>British Journal of Cancer</i> , 2010, 103, 560-566.	2.9	34
52	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1007-1007.	0.8	34
53	Prevalence and Treatment Management of Oropharyngeal Candidiasis in Cancer Patients: Results of the French Candidoscope Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 532-539.	0.4	33
54	Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 2046-2052.	0.6	33

#	ARTICLE	IF	CITATIONS
55	Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 12-21.	2.0	32
56	Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes. <i>Frontiers in Oncology</i> , 2018, 8, 112.	1.3	31
57	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. <i>European Journal of Cancer</i> , 2020, 135, 130-146.	1.3	31
58	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012, 21, 20-26.	0.9	30
59	Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the <sc>CAVECCAS</sc> study. <i>Cancer Medicine</i> , 2017, 6, 2732-2744.	1.3	30
60	Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: Focus on clinical trials and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 115-128.	2.0	29
61	Cardiovascular Safety Profiles of Aromatase Inhibitors. <i>Drug Safety</i> , 2006, 29, 785-801.	1.4	25
62	Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. <i>Annals of Oncology</i> , 2011, 22, 1582-1587.	0.6	25
63	Does Concurrent Radiochemotherapy Affect Cosmetic Results in the Adjuvant Setting After Breast-Conserving Surgery? Results of the ARCOSEIN Multicenter, Phase III Study: Patients' and Doctors' Views. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 66-72.	0.4	23
64	Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E83-E89.	0.9	23
65	A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. <i>Annals of Oncology</i> , 2014, 25, 1775-1782.	0.6	23
66	Optimal Sequence of Implied Modalities in the Adjuvant Setting of Breast Cancer Treatment: An Update on Issues To Consider. <i>Oncologist</i> , 2010, 15, 1169-1178.	1.9	22
67	Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network. <i>Breast</i> , 2018, 40, 10-15.	0.9	22
68	High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 3053-3058.	3.2	21
69	Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial Experience. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1806-1809.	0.9	21
70	Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial. <i>Cancer Research</i> , 2019, 79, GS3-07-GS3-07.	0.4	20
71	Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?. <i>British Journal of Cancer</i> , 2013, 109, 1147-1156.	2.9	19
72	Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. <i>Joint Bone Spine</i> , 2000, 67, 22-9.	0.8	18

#	ARTICLE	IF	CITATIONS
73	Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2011, 22, 321-328.	0.6	17
74	Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 421-428.	1.1	17
75	Weekly paclitaxel still preferred first-line taxane for mBC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 508-509.	12.5	17
76	An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. <i>PLoS ONE</i> , 2020, 15, e0227356.	1.1	17
77	Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. <i>Surgical Oncology</i> , 2010, 19, e47-e55.	0.8	16
78	Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 601-607.	1.1	16
79	HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 123-133.	2.0	16
80	Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1555-1564.	0.9	15
81	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. <i>Breast</i> , 2017, 34, 89-95.	0.9	15
82	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 197, 113968.	1.4	15
83	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	3.4	15
84	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. <i>Journal of Medical Economics</i> , 2012, 15, 1167-1175.	1.0	13
85	Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 4749.	1.7	13
86	Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. <i>European Journal of Cancer</i> , 2011, 47, 2396-2402.	1.3	12
87	Discordance With Local Guidelines for Adjuvant Chemotherapy in Breast Cancer: Reasons and Effect on Survival. <i>Clinical Breast Cancer</i> , 2011, 11, 46-51.	1.1	12
88	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. <i>SpringerPlus</i> , 2016, 5, 45.	1.2	12
89	Patient database analysis of fulvestrant 500mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017, 32, 247-255.	0.9	12
90	Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. <i>Oncologist</i> , 2018, 23, 1137-1143.	1.9	12

#	ARTICLE	IF	CITATIONS
91	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 383-393.	1.1	12
92	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
93	Docetaxel in the treatment of breast cancer: current experience and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 613-633.	1.1	11
94	Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. <i>Breast</i> , 2007, 16, 1-9.	0.9	11
95	Impact of screening on clinicopathological features and treatment for invasive breast cancer: Results of two national surveys. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 295-302.	0.6	10
96	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
97	IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2017, 28, v105.	0.6	10
98	Concurrent trastuzumab and Internal mammary irradiation for HER2 positive breast cancer: it hurts to be on the cutting edge. <i>Radiotherapy and Oncology</i> , 2010, 94, 119-120.	0.3	9
99	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. <i>European Journal of Cancer</i> , 2020, 136, 1-3.	1.3	9
100	Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.. <i>Journal of Clinical Oncology</i> , 2012, 30, 568-568.	0.8	9
101	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open Cancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	2.0	8
102	Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2015, 48, 13-24.	0.7	7
103	Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy. <i>Cancer Cell International</i> , 2018, 18, 175.	1.8	7
104	Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. <i>European Journal of Medical Genetics</i> , 2020, 63, 104098.	0.7	7
105	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509.	1.7	7
106	Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021, 55, 79-90.	0.9	7
107	Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé À La Grossesse) network. <i>Acta Oncologica</i> , 2022, 61, 302-308.	0.8	7
108	The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 237-249.	0.4	6

#	ARTICLE	IF	CITATIONS
109	Breast cancer metastasis to the spleen: a case report and literature review. Oxford Medical Case Reports, 2017, 2017, omx069.	0.2	6
110	Supporting multidisciplinary staff meetings for guideline-based breast cancer management: a study with OncoDoc2. AMIA ... Annual Symposium proceedings, 2007, , 656-60.	0.2	6
111	Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Bone Marrow Transplantation, 2006, 37, 669-675.	1.3	5
112	Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC). Annals of Oncology, 2012, 23, ix114-ix115.	0.6	5
113	Long-term complete response in a breast cancer patient with skeletal muscle metastases diagnosed using 18F-FDG-PET. Oxford Medical Case Reports, 2017, 2017, omx002.	0.2	5
114	Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial. Annals of Oncology, 2019, 30, v141.	0.6	5
115	ï½volution de la revue et nouveaux objectifs 2005. Oncologie, 2005, 7, 1-2.	0.2	4
116	Formation mï½dicale continue. Oncologie, 2005, 7, 3-3.	0.2	4
117	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy, 2010, 10, 1825-1836.	1.1	4
118	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in ÅHER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. European Journal of Cancer, 2017, 81, 151-160.	1.3	4
119	Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study. , 2013, , .		4
120	Breast Cancer Management during the COVID 19 Pandemic: French Guidelines. The Journal of Breast Health, 2020, 16, 160-161.	0.4	4
121	Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study. Breast, 2022, 64, 151-158.	0.9	4
122	A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular Cancer. New England Journal of Medicine, 1999, 341, 1475-1476.	13.9	3
123	Bonne anne Å©, bonne sant Å©, bonne FMCI!. Oncologie, 2006, 8, 1-1.	0.2	3
124	St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patientsâ€™ overtreatment and breaking the bank?. Annals of Oncology, 2019, 30, 1533-1535.	0.6	3
125	Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associ Å© Å La Grosse) network. Breast, 2020, 54, 311-318.	0.9	3
126	Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Results of the IRMA study. Journal of Clinical Oncology, 2006, 24, 8603-8603.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Incidence and Risk Factors for Central Venous Catheter-Related Venous Thromboembolism in Breast Cancer Patients Under Neoadjuvant Chemotherapy: the Caveccas (Catheter Veineux Central et Cancer) Tj ETQq1 106784314rgBT /O	0.7	2
128	Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC). , 2018, , .		3
129	Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associé à la Grossesse) network. Breast, 2022, 61, 168-174.	0.9	3
130	Taxane Therapy for Early Stage Breast Cancer. Women's Health, 2006, 2, 99-114.	0.7	2
131	192. International Journal of Radiation Oncology Biology Physics, 2006, 66, S107.	0.4	2
132	Cancer du sein. , 2007, , .		2
133	RPC Saint-Paul-de-Vence: deuxi�me. Oncologie, 2007, 9, 591-592.	0.2	2
134	Castration-Dependent Pharmacokinetics of Docetaxel: Do Sex and/or ABCB1 Polymorphism Also Matter?. Journal of Clinical Oncology, 2011, 29, e454-e455.	0.8	2
135	A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. Chemotherapy, 2016, 61, 15-22.	0.8	2
136	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. Future Oncology, 2021, 17, 151-157.	1.1	2
137	Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study). , 2017, , .		2
138	Creating Synthetic Patients to Address Interoperability Issues: A Case Study with the Management of Breast Cancer Patients. Studies in Health Technology and Informatics, 2020, 275, 177-181.	0.2	2
139	Aux conteurs d��histoires.... Oncologie, 2005, 7, 339-340.	0.2	1
140	Fight against cancer around the Mediterranean area: ��Many hands make light work!�� Critical Reviews in Oncology/Hematology, 2012, 84, e1-e5.	2.0	1
141	Bevacizumab��Capecitabine (BEV��CAP) After Initial 1st-Line Bevacizumab��Docetaxel (BEV��DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of the IMELDA Trial. Annals of Oncology, 2012, 23, ix128.	0.6	1
142	Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon cancer. Kidney International, 2013, 84, 420.	2.6	1
143	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. Annals of Oncology, 2016, 27, vi43.	0.6	1
144	An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies. Annals of Oncology, 2016, 27, vi63.	0.6	1

#	ARTICLE	IF	CITATIONS
145	First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count. <i>Annals of Oncology</i> , 2016, 27, vi69.	0.6	1
146	Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability. <i>Annals of Oncology</i> , 2016, 27, vi63.	0.6	1
147	Patients with delirium and advanced solid cancer in the emergency department: A challenge for the emergency practitioner, oncologist, and intensivist. <i>Cancer</i> , 2017, 123, 704-705.	2.0	1
148	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 107-116.	1.1	1
149	Early HER2-positive breast cancers: time for a new revolution?. <i>Lancet Oncology</i> , The, 2018, 19, 12-13.	5.1	1
150	The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. <i>European Journal of Cancer</i> , 2018, 92, S105-S106.	1.3	1
151	Predicting the likelihood of recurrence of pregnancy-associated breast cancer: Nomogram based on analysis of the French cancer network: Cancer Associati�� La Grosse. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 101766.	0.6	1
152	Optimisation du nomogramme de r��ponse �� la chimioth��rapie n��o-adjuvante du MDACC pour un sch��ma utilisant plus de 4 cycles d��anthracycline. , 2012, , 358-359.		1
153	Abstract P6-07-05: Interactions between adipocyte stem cells and normal or tumoral mammary epithelial cells. Potential role of BRCA status and estrogen pathway. , 2018, , .		1
154	A phase I study combining high-dose (HD) topotecan (TPC) plus cyclophosphamide (CPM) with blood stem cells support in poor prognosis ovarian carcinoma (OC): The ITOV 01bis protocol. <i>Journal of Clinical Oncology</i> , 2007, 25, 16061-16061.	0.8	1
155	A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS625-TPS625.	0.8	1
156	Efficacy of epirubicin-paclitaxel (EPI-TAX) prior to high-dose chemotherapy (HDCT) in germ cell tumors (GCTs): A 17-year experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4557-4557.	0.8	1
157	Emilia: use cunning to survive cancer. <i>Chinese Clinical Oncology</i> , 2018, 7, 5-5.	0.4	1
158	Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 603-603.	0.8	1
159	Neglected giant benign phyllode tumor of the breast. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3954-3955.	3.3	1
160	Thrombose r��versible de lâ��art��re pulmonaire. <i>Revue De Medecine Interne</i> , 1995, 16, 265s-266s.	0.6	0
161	Genetic Abnormalities in Synovial Sarcoma. <i>New England Journal of Medicine</i> , 1998, 338, 1699-1699.	13.9	0
162	Oncologie Recherche Clinique: mi��ci��ne de l��art canci��rologique ?. <i>Oncologie</i> , 2004, 6, s55-s56.	0.2	0

#	ARTICLE	IF	CITATIONS
163	«Prêt-à-porter ou sur-mesure?». <i>Oncologie</i> , 2005, 7, s71-s73.	0.2	0
164	Raison et progrès. <i>Oncologie</i> , 2006, 8, S1-S2.	0.2	0
165	Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. <i>Targeted Oncology</i> , 2006, 1, 228-238.	1.7	0
166	Comment définir ce que l'on ne connaît pas ?. <i>Oncologie</i> , 2007, 9, 73-74.	0.2	0
167	La recherche clinique dans le domaine du cancer du sein: État des lieux et perspectives. <i>Oncologie</i> , 2009, 11, 319-324.	0.2	0
168	Détermination de HER2 dans les adénocarcinomes pour établir le pronostic et prédire la réponse aux traitements. <i>Oncologie</i> , 2010, 12, 416-421.	0.2	0
169	Looking for predictive markers in breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e1-e2.	5.1	0
170	Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). <i>Annals of Oncology</i> , 2016, 27, vi533.	0.6	0
171	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PreHer study. <i>Annals of Oncology</i> , 2016, 27, vi63.	0.6	0
172	Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study. <i>Annals of Oncology</i> , 2016, 27, vi85.	0.6	0
173	Breast cancer prognosis after neoadjuvant chemotherapy for breast cancers: molecular downstaging, proliferation, and endocrine sensitivity importance. <i>Annals of Oncology</i> , 2016, 27, vi56.	0.6	0
174	PONDx: a prospective multicenter French study of the 21-gene assays: impact on treatment selection in patients with high-risk breast cancer. <i>Breast</i> , 2017, 32, S61.	0.9	0
175	Cancer de mama inflamatorio. <i>EMC - Ginecología-Obstetricia</i> , 2017, 53, 1-9.	0.0	0
176	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , 2017, 1, 213-219.	0.3	0
177	Real-life utilization of genomic testing for invasive breast cancer patients in Italy and France reduces chemotherapy recommendations. <i>Annals of Oncology</i> , 2018, 29, viii61.	0.6	0
178	Impact of BRCA status on outcomes and survival in high-risk early breast cancers. <i>Annals of Oncology</i> , 2018, 29, viii68.	0.6	0
179	Multicenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study. <i>Annals of Oncology</i> , 2019, 30, v124-v125.	0.6	0
180	STANDARDS OF CARE AND OPTIMAL OPTIONS FOR LUMINAL ABC. <i>Breast</i> , 2019, 48, S27-S28.	0.9	0

#	ARTICLE	IF	CITATIONS
181	1773P Mainstreamed genetic testing for French breast and ovarian cancer patients and its utility during the COVID-19 pandemic. <i>Annals of Oncology</i> , 2020, 31, S1028.	0.6	0
182	Severe acute respiratory syndrome Coronavirus 2 infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?. <i>International Journal of Cancer</i> , 2020, 147, 3576-3578.	2.3	0
183	Critères de choix d'une chimiothérapie adjuvante. , 2013, , 92-112.		0
184	Abstract CT081: High-dose chemotherapy associated with bevacizumab for metastatic germ cell tumors: the TAXIF 3 trial. , 2016, , .		0
185	Abstract P5-15-06: Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). , 2017, , .		0
186	Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?. <i>Chinese Clinical Oncology</i> , 2018, 7, 1-1.	0.4	0
187	Abstract OT1-03-01: Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study. , 2018, , .		0
188	Abstract CT140: Circulating tumor cells as a tool to guide first line therapy in metastatic breast cancer: sub-group analyses of the STIC CTC Phase III utility trial. , 2019, , .		0
189	Abstract P2-16-22: Can we improve pCR prediction in early breast cancers treated with neoadjuvant chemotherapy using a simple machine learning algorithm based on 18-FDG and clinico-pathological parameters?. , 2020, , .		0
190	Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial. , 2020, , .		0
191	Abstract P2-11-13: Specific aspect of utilization of the prognostic multigene assay for invasive lobular carcinoma at early stage: Oncotype Dx in the prospective French cohort PONDx. , 2020, , .		0